Topic Listing for XTENT

Accrued Liabilities Additional Change Control Provisions
Address Aggregated Option Exercises 2006
Aggregated Option Exercises 2008 Allan
Amendment Amendment Equity Incentive Plan
Amendment Lease Amendment Modification Revocation Plan Dissolution
Amendment Restated Agreement Amended Only Written Executed Xtent Amount Distribute Stockholders Pursuant Plan Dissolution Substantially Less
Annual Meeting Stockholders Anti-takeover Provisions Amended Restated Certificate Incorporation Bylaws Delaware
Appendix Prices Appendix Product Specifications
Approval Plan Dissolution Arthur Taylor
Assets Measured Fair Value Nonrecurring Basis Assignment
Associate Director Center Interventional Vascular Therapy Audit Committee
Audit Fees Authority Officers Directors
Available Available Information
Award Agreement Balloon Angioplasty
Bare Metal Stent Systems Bare Metal Stents
Base Salary Basis Presentation
Because Operated Private Experience Complying Public Obligations Including Beneficial Conversion Feature
Beneficial Ownership Reporting Compliance Beneficial Stockholders
Bernard Andreas Bioabsorbable Stent Systems
Bioabsorbable Stent Technology Biosensors Fails Supply Sufficient Quantities Drug Coating Development
Biosensors Fails Supply Sufficient Quantities Drug Coating Test Biotechnology Peers
Board Committee Meetings Board Directors Revoke Implementation Plan Dissolution Even Approved
Breach Covenants Agreements Xtent Restated Agreement Brian Walsh
Business Overview Buyers Representatives
Cancellation Cancellation Common Stock
Cash Equivalents Cash Flows
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Cash Payment Dollars Initial Licensing Fee
Certain Relationships Related Transactions Director Independence Certification Chief Executive Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Executive Officer Pursuant Usc 1350 Adopted Certification Chief Financial Officer Pursuant 302 Sarbanes-oxley Act
Certification Chief Financial Officer Pursuant Usc 1350 Adopted Cgmp Besa Provided Hereunder Meet Applicable Regulatory Requirements
Changes Changes Amended Plan
Changes Internal Control Over Financial Reporting Changes Interpretations Accounting Rules Regulations Such Expensing Stock
Changes Securities Proceeds Christopher Smith
Classes Board Directors Clinical Trial Accruals
Clinical Trials Clinical Trials Necessary Support Pma Application Expensive Require
Coating Purchases Formulation Code
Code Business Conduct Ethics Collaborative Planning
Commitments Contingencies Common Stock
Communications Board Directors Comparison 2004 2005
Comparison 2005 2006 Comparison 2006 2005
Comparison 2007 2006 Comparison 2008 2007
Compensation Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Discussion Analysis
Compensation Program Objectives Philosophy Competition
Competitors Much Larger Significant Resources Incentives Initiate Litigation Components Executive Compensation
Comprehensive Income Loss Concentration Credit Risk
Condensed Balance Sheets Conference Call Today
Conference Call Webcast Information Confidentiality
Consent Independent Registered Public Accounting Firm Consideration Director Nominees
Contingencies Continue Incur Expenses Complying Public Reporting Requirements Economically
Contractual Obligations Controls Procedures
Controls Procedures Disclosure Conversion
Coronary Artery Bypass Graft Surgery Corporate Governance
Cost Drug Coating Other Components Stent Systems Increase Costs Associated Exit Disposal Activities
Counsel Capital Llc Counterpart Copies
Creation Direct Financial Obligation Off-balance Sheet Arrangement Critical Accounting Policies Estimates
Currently Not Never Products Available Sale Efforts Obtain Custom
Custom Care Custom Des System
Custom Long Multi-lesion Trial Six-month Data Presented Europcr Customizable Drug Eluting Balloon Technology
Date Report Earliest Event Reported Xtent Inc Default
Defaults Senior Securities Definitions
Delivery System Delivery Terms
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Certain Officers Election Appointment Compensatory Arrangements
Depend Certain Officers Not Able Retain Them Recruit Depend Officers Not Able Retain Them Recruit Additional
Depend President Chief Executive Officer Not Able Retain Depend Single-source Suppliers Some Components Custom Des Systems
Description Common Clinical Measures Development Stage History Losses Expect Incur Net Foreseeable
Diligence Limited Exclusivity Director Compensation
Director Independence Director Qualifications
Directors Continuing Office Until 2008 Directors Continuing Office Until 2009
Directors Continuing Office Until 2010 Directors Officers Principal Stockholders Significant Voting Power Take
Disclosure Controls Procedures Dispute Resolution
Disputes Dissolution Liquidation
Dividends Dmf Maf Biolimus Pla Formulation Specific Xtent
Documents Incorporated Reference Drug Eluting Stents
Edward Unkart Electronic Delivery Stockholder Communications
Employee Benefit Plans Employee Stock Purchase Plan
Employees Employment Agreements
Encumbrance Title Besa Provided Hereunder Shall Pass Herein Entry Material Definitive Agreement
Equity Incentive Awards Outstanding 2007 Equity Incentive Plan
Estimates Even Obtain Additional Funding Complete Strategic Transaction Provides
Even Products Approved Regulatory Authorities Suppliers Fail Comply Even Successful Completing Strategic Transaction Nature Such Require
Evolution Delivery Methods Percutaneous Coronary Interventions Evolution Treatments Coronary Artery Disease
Exchange Rate Risk Exclusivity
Executive Officers Executive Time Off
Exhibits Expanded Range Stent Diameters
Expect Price Common Stock Fluctuate Substantially Explanatory
Exploring Strategic Alternatives Such Potential Merger Sale Some Face Risk Product Liability Claims Not Able Obtain
Fail Obtain Adequate Level Reimbursement Products Third-party Payors Failure Obtain Regulatory Approval Foreign Jurisdictions Prevent Marketing
Fair Value Financial Instruments Fair Value Measurements
Fdas Premarket Clearance Approval Requirements Federal Tax Aspects
Fees Paid Independent Auditors Filing Tax Returns Forms Other Reports Statements
Financial Statements Exhibits Financing Activities
Fold Detach Here Force Majeure
Form 10-k Form 10-q
Forward Looking Statements Fraud Abuse
Further Stockholder Approval Not Required Connection Implementation Plan Gaap Means Generally Accepted Accounting Principles Consistently Applied
General General Administrative
Gerbsman Partners Gerbsman Partners Compensation
Governing Law Language Grants Plan-based Awards 2007
Gregory Casciaro Guarantee Success
Hazardous Material Packaging Labeling Shipping Henry Plain
Highlights Identifying Evaluating Director Nominees
Impairment Long-lived Assets Import Export Sell Offer Sale Xtents Stents Utilizing
Incentive Stock Options Income Taxes
Indemnification Indemnifications
Independence Parties Independent Compensation Consultant
Index Financial Statements Information
Infringement Indemnity Initial Public Offering
Insert Vesting Schedule Intellectual Property
Interest Income Interest Other Income Expense Net
Interest Other Income Net Interest Rate Risk
International Internet Telephone Vote Authorizes Named Proxies Shares Same
Introduction Investing Activities
Investments Involving Stock Compensation
Jeffry Grainger Lawsuit Whether Initiated Enforce Intellectual Property Rights Party
Leases Legislative Regulatory Reform Healthcare System Affect Ability Sell
License Agreement License Agreements
Licensed Assets Means Patents Know-how Licensed Patents Prosecution Defense
Limitation Audit Committees Role Limitations Current Percutaneous Coronary Intervention Therapies
Limitations Liability Indemnification Limited Device Manufacturing Drug Coating Capabilities Personnel Facilities
Limited Experience Complying Public Obligations Including Recently Enacted Liquidating Distributions
Liquidating Distributions Stockholders Delayed Diminished Liquidating Trust
Liquidation Liquidation Code Sections 331 336
Liquidation Dissolution Liquidity Capital Resources
Loss Impairment Long-lived Assets Managements Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Facilities Suppliers Comply Strictly Enforced Regulatory Requirements
Manufacturing Lead Times Market Opportunity
Market Registrants Common Equity Related Stockholder Matters Issuer Material Federal Income Tax Consequences
Material Federal Income Tax Consequences Stockholders Medical Device Peers
Members Board Directors Membership Requirements
Menlo Park Calif 2007 Menlo Park Calif 2008
Menlo Park Calif 2008- Menlo Park Calif 2009
Michael Carusi Michael Eagle
Millimed Contract Minimum Orders
Need Substantial Additional Funding Unable Raise Capital Adequate Need Substantial Additional Funding Unable Raise Capital Needed
Net Loss Per Common Share Nominating Corporate Governance Committee
Nominee Director Three-year Term Ending 2010 Nominees Directors Three-year Term Ending 2011
Non-compliance Other Documents Supply Agreement Non-employee Stock-based Compensation
Non-equity Earning Potential Non-equity Incentive Programs
Nonqualified Deferred Compensation Nonstatutory Stock Options
Not Achieve Projected Development Goals Time Frames Announce Not Long-term Data Regarding Safety Efficacy Custom Des
Not Paid Dividends Past Expect Pay Future Return Not Received Never Receive Fda Other Regulatory Approvals
Not Successful Efforts Expand Portfolio Products Develop Additional Notice 2007 Annual Meeting Stockholders Held
Notice Procedures Number 001-33282
Number Awards Granted Employees Consultants Directors Off-balance Sheet Arrangements
Operating Activities Operating Capital Expenditure Requirements
Operating Lease Operating Lease Commitments
Operations Involve Hazardous Materials Comply Environmental Laws Regulations Organization
Other Events Other Fees
Other Information Other Matters
Other Obligation Kind Express Implied Name Behalf Party Over-the-wire
Overview Packing
Part Partial Invalidity Agreement
Parties Hold Large Number Patents Related Stents Not Parties Rely Conduct Clinical Trials Assist Pre-clinical Development
Party Reimbursement Patient Characteristics
Patients Characteristics Patrick Latterell
Payments Peer Companies
Peripheral Applications Pervasive Continuing Regulation
Philippe Marco Physicians Not Widely Adopt Custom Des Systems Unless
Plan Planned Clinical Trials
Policies Procedures Related Party Transactions Post-approval Registries
Potential Payments Following Change Control Pre-clinical Studies Clinical Trials Not Meet Safety Efficacy
Precedence Preferred Stock
Price Payment Terms Principal Accountant Fees Services
Problems Stent Used Control Group Pivotal Clinical Trial Problems Stent Used Control Group Planned Pivotal Clinical
Procedure Product Modifications
Product Warranties Besa Warrants Represents Products
Products Based New Technology Only Limited Experience Regulatory Products Development
Professional Fees Expenses Properties
Property Equipment Proposal Two-ratification Appointment Independent Registered Public Accounting Firm
Proposals Board Directors Recommends Vote Proprietary Rights
Proxy Statement 2007 Annual Meeting Stockholders Held Proxy Voted Directed Indication Proposals Discretion Holders Such
Purchase Commitments Purpose
Pursuant 302 Sarbanes-oxley Act 2002 Quantitative Qualitative Disclosures Market Risk
Quantities Quick Deployment Handles
Randolph Campbell Rapid Exchange
Recent Accounting Pronouncements Recent Adopted Accounting Pronouncements
Recent Developments Recitals
Recordation Transfers Common Stock Transfer Books Restricted Future Recording Compensation Expense Result Increase Net Losses Given
Redeemable Convertible Preferred Stock Reduction Force
Regulatory Filing Process Regulatory Update
Related Party Transactions Relationship Biosensors
Remainder Page Intentionally Left Blank Replacement Prior Agreements
Report Audit Committee Report Compensation Committee
Report Independent Registered Public Accounting Firm Representations Warranties Besa
Representations Warranties Xtent Required Clinical Trials
Research Development Restated Agreement
Restated Agreement Used Words Including Includes Deemed Followed Restricted Cash
Restricted Common Stock Results Operations Financial Condition
Revenue Revenue Did Not Generate 2007 2006 Research Development
Reverse Stock Split Right Return
Risks Related Commercialization Risks Related Continuing Business Operations Plan Dissolution Not
Risks Related Plan Dissolution Risks Uncertainties
Robert Bellas Robert Flaherty
Royalties Royalty Bearing Product Means Stent System Sold Xtent
Royalty Milestone Obligations Sale Substantial Number Shares Common Stock Cause Price
Sales Marketing Sarbanes-oxley Act 2002
Schedule 14a Scope Engagement
Securities Authorized Issuance Equity Compensation Plans Securities Registered Pursuant Act
Segment Information Short-term Investments
Signature Page Follows Signatures
Signatures Begin Next Page Six-month Custom Long Multi-lesion Clinical Trial Data Presented
Sources Liquidity Special Meeting Stockholders Held 2009
Status Regulatory Approval Stent Drug Coating
Stock Information Stock Option Award Agreement
Stock Option Grants Stock Option Plans
Stock Performance Graph Stock Plan
Stock-based Compensation Stockholder Nominations Recommendations
Stockholders Stockholders Lose Opportunity Capitalize Potential Growth Opportunities Continuation
Stockholders Not Able Recognize Loss Federal Income Tax Stockholders Not Approve Plan Dissolution Resources Diminish Completely
Stockholders Not Approve Plan Dissolution Stock Price Adversely Stockholders Record
Strategy Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Summary Cash Flows Summary Compensation Table
Summary Significant Accounting Policy Update Supply Agreement
Target Pay Position Targeted Compensation
Tariff Provisions Tax Consequences
Tax Fees Tax Service Fees
Technology Platform Term Sheet Means Non-binding Executed Xtent Occam
Term Termination Agreement Termination Cause
Termination Period Terms License Agreement Biosensors Price Pay Drug Coating
Third-party Patent Rights Timothy Kahlenberg
Title Class Traceability Audits Quality System
Unable Establish Sales Marketing Capabilities Enter Maintain Arrangements Unable Manage Expected Growth Not Able Commercialize Products
Unable Obtain Maintain Intellectual Property Protection Covering Products United States
Unregistered Sales Equity Securities Proceeds Validity
Vesting Schedule Volatility Stock Price Other Companies Contribute
Vote Important Vote Internet
Vote Proxy Internet Telephone Not Need Mail Back Vote Required
Vote Telephone Voting
Voting Proxy Warranties
Xtent Xtent Announces 2007 Financial Results
Xtent Announces 2008 Financial Results Xtent Announces 2008 Financial Results Business Progress
Xtent Announces Plan Nasdaq Delisting Filing Certificate Dissolution Xtent Announces Year-end 2006 Financial Results
Xtent Inc Xtent Inc Announces Approval Plan Liquidation Dissolution Board
Xtent Inc Development Stage Condensed Balance Sheets Xtent Inc Index Financial Statements
Xtent Solution Xtents Indemnified Persons Means Xtent Directors Officers Shareholders
Xtents Licenses Xtents Rights Event Supply Failure
Year-end 2006 Financial Results 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki